Atogepant (Qulipta) for Migraine Prevention

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2021年 / 63卷 / 1636期
关键词：
DOUBLE-BLIND;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：169 / 171
页数：3
相关论文
共 50 条
  • [31] Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis
    Tassorelli, Cristina
    Onishchenko, Kateryna
    Singh, Rashmi B. Halker
    Duan, Molly
    Dupont-Benjamin, Laure
    Hemstock, Matthew
    Voller, Corey
    McAllister, Peter
    Nahas, Stephanie J.
    Gandhi, Pranav
    Ailani, Jessica
    CEPHALALGIA, 2024, 44 (02)
  • [32] Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results from a Phase 2b/3 Study
    Goadsby, P. J.
    Dodick, D. W.
    Ailani, J.
    Trugman, J. M.
    Finnegan, M.
    Lakkis, H.
    Lu, K.
    Szegedi, A.
    HEADACHE, 2019, 59 : 18 - 19
  • [33] Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results From a Phase 2b/3 Study
    Goadsby, Peter J.
    Dodick, David W.
    Ailani, Jessica
    Trugman, Joel M.
    Finnegan, Michelle
    Lakkis, Hassan
    Lu, Kaifeng
    Szegedi, Armin
    CEPHALALGIA, 2019, 39 : 182 - 183
  • [34] Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis
    Peterlin, B. Lee
    Bond, Dale S.
    Ailani, Jessica
    Dodick, David W.
    Liu, Yingyi
    Ferreira, Rosa De Abreu
    Smith, Jonathan H.
    Dabruzzo, Brett
    Goadsby, Peter J.
    Trugman, Joel M.
    CEPHALALGIA, 2024, 44 (12)
  • [35] Impact of Atogepant on Migraine-Specific QoL Among Individuals With Episodic Migraine and Preventive Treatment Failure
    Tassorelli, C.
    Gandhi, P.
    Sacco, S.
    Pozo-Rosich, P.
    Lanteri-Minet, M.
    Nezadal, T.
    Trugman, J.
    Luo, L.
    Stokes, J.
    Nagy, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 214 - 215
  • [36] Comparison of atogepant vs rimegepant in refractory chronic migraine: A retrospective analysis
    Baek, William
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [37] Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine
    Wells-Gatnik, William David
    Pellesi, Lanfranco
    Martelletti, Paolo
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2024, 24 (11) : 1107 - 1117
  • [38] Daily atogepant for the preventive treatment of migraine increases responder rates for reduction in mean monthly migraine days
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Dodick, D. W.
    McAllister, P.
    Li, Y.
    Lu, K.
    Dabruzzo, B.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2021, 61 : 118 - 118
  • [39] EFFICACY, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED ATOGEPANT FOR THE PREVENTION OF EPISODIC MIGRAINE: RESULTS FROM A PHASE 2B/3 STUDY
    Goadsby, P. J.
    Dodick, D. W.
    Trugman, J. M.
    Finnegan, M.
    Lakkis, H.
    Lu, K.
    Szegedi, A.
    CEPHALALGIA, 2018, 38 : 144 - 145
  • [40] Efficacy, Safety, and Tolerability of Orally Administered Atogepant for the Prevention of Episodic Migraine: Results from a Phase 2b/3 Study
    Goadsby, Peter J.
    Dodick, David W.
    Trugman, Joel M.
    Finnegan, Michelle
    Lakkis, Hassan
    Lu, Kaifeng
    Szegedi, Armin
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
12345